Neo Kuma Ventures

Neo Kuma Ventures, established in 2020 and headquartered in London, is Europe’s largest VC fund focused exclusively on psychedelic healthcare. Neo Kuma aims to revolutionize the treatment of mental health conditions such as depression, PTSD, addiction, and chronic pain through investments in cutting-edge psychedelic therapies. They invest in early-stage companies (Pre-Seed to Series A), deploying capital in the range of £150k to £1 million, with a particular focus on clinical research and digital therapeutics. Neo Kuma's portfolio includes significant players in the field, such as ATAI Life Sciences, Beckley Psytech, and Small Pharma, companies that are advancing the frontiers of mind-altering medicines and therapeutic platforms. Neo Kuma’s strategy is hands-on, working closely with founders to navigate both scientific development and regulatory challenges in this emerging market. The firm is led by a team of experienced investors like Clara Burtenshaw and Sean McLintock, both of whom bring a wealth of expertise in biotech, venture capital, and finance. Neo Kuma is not only a financial backer but also a policy influencer, collaborating with leading organizations in psychedelic research, such as the International Therapeutic Psilocybin Rescheduling Initiative. This integrated approach positions Neo Kuma as a key player in reshaping the future of mental healthcare through psychedelics.